The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Tue., Oct. 17, 9:41 PM

Slide #2. Abeona Therapeutics Inc. Secondary Offering

Company: Abeona Therapeutics Inc. (NASDAQ:ABEO)
Date announced: 10/16/2017
Shares Offered: 5,000,000
Date of Pricing: 10/16/2017
Price Per Share: $16.00
Secondary Offering Details: Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering pursuant to an existing shelf registration statement. All of the shares in the offering are to be sold by Abeona. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies LLC is acting as sole book-running manager for the offering. Abeona intends to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares sold in the offering, on the same terms and conditions. -updated 10/16- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, today announced the pricing of an underwritten public offering of five million shares of common stock at a public offering price of $16.00 per share. The gross offering size for this offering is expected to be approximately $80 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 750,000 shares of common stock. The offering is expected to close on or about October 19, 2017, subject to customary closing conditions.

Abeona Therapeutics is a clinical stage biopharmaceutical company developing gene therapies for life-threatening rare genetic diseases. Co.'s primary programs are ABO-102 and ABO-101, adeno-associated virus based gene therapies for Sanfilippo syndrome. Co. also develops EB-101, gene-corrected skin grafts for recessive dystrophic epidermolysis bullosa; EB-201 for epidermolysis bullosa; ABO-201, gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301 for Fanconi anemia disorder; and ABO-302 for rare blood diseases. Co. has a plasma-based protein therapy platform, using its proprietary SDFTM (Salt Diafiltration) ethanol-free process.

ABEO SEC Filing Email Alerts Service

Open the ABEO Page at The Online Investor »

Company Name:  Abeona Therapeutics Inc
Website:  www.abeonatherapeutics.com
Sector:  Biotechnology
Number of ETFs Holding ABEO:  11
Total Market Value Held by ETFs:  $17.28M
Total Market Capitalization:  $649.00M
% of Market Cap. Held by ETFs:  2.66%
 

Open the ABEO Page at The Online Investor (in a new window) »

October 17, 2017    9:41 PM Eastern
Quotes delayed 20 minutes



Strong Buy (3.83 out of 4)
81st percentile
(ranked higher than approx. 81% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2017, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.